


PHARMACEUTICAL 2018

SYNLOGIC INC. Rank 79 of 342









PHARMACEUTICAL 2018

SYNLOGIC INC. Rank 79 of 342



The relative strengths and weaknesses of SYNLOGIC INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SYNLOGIC INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 81% points. The greatest weakness of SYNLOGIC INC. is the variable Research and Development, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 185%, being 140% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	88,589
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,027
Liabilities, Non-Current	5,634
Other Assets	1,327
Other Compr. Net Income	-9.0
Other Expenses	0
Other Liabilities	0
Other Net Income	447
Other Revenues	2,444
Property and Equipment	9,783
Research and Development	30,341
Selling, General and Administrative Expense	12,927

Output Variable	Value in 1000 USD
Assets	99,699
Liabilities	14,661
Expenses	43,268
Revenues	2,444
Stockholders Equity	85,038
Net Income	-40,377
Comprehensive Net Income	-40,382
Economic Capital Ratio	185%

